QLT at neutral by Merrill

QLT Inc. was rated at neutral by Merrill Lynch analyst Hari Sambasivam following ARVO 2006. Key themes included dominance of Avastin and Lucentis in AMD. Widespread use of Avastin is being driven by its cost and availability prior to Lucentis' final approval and launch. Shares of the Vancouver, B.C. biopharmaceutical company were down $0.02 or 0.24%, at $8.16 on volume of 716,764 shares versus the three-month running average of 1,429,470 shares. (Nasdaq: QLTI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.